Select Page

Press Releases

Sign up to get full access to all our latest Press Releases

Rapid Dose Therapeutics Announces Operational Changes

March 23, 2020


Burlington, Ontario – March 23, 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”) announces that operations at its Burlington, Ontario facility have been curtailed due to a number of reasons including the recent dramatic drop in North American stock markets, the...

Rapid Dose Therapeutics Announces Investment Agreement With Institutional Investor

March 5, 2020


Burlington, Ontario – March 5, 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation“) today announced that it has entered into an agreement for a drawdown equity financing facility (the “Investment Agreement”) with a single institutional investor. Subject to its terms and...

Rapid Dose Therapeutics Announces Nutraceutical Reseller Agreement for Canada, United States and India

February 27, 2020


Burlington, Ontario – February 27, 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce an Agreement with Perennial Brands, a DCM company, for the distribution and sale of nutraceutical oral dissolvable strip products in Canada, the United States...

Rapid Dose Therapeutics Announces Issuance of CRA Cannabis Licence and Board and Management Changes

February 21, 2020


Burlington, Ontario – February 21, 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce receipt of its Canada Revenue Agency (CRA) Cannabis Licence in February 2020, and now has obtained all approvals for cannabis processing and packaging for...

Rapid Dose Therapeutics Receives Funding for Scale-Up Manufacturing and Commercialization of Quickstrip™ Product

February 4, 2020


Burlington, Ontario – February , 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation“) is pleased to announce the company has secured government funding of $400,000 from The National Research Council of Canada Industrial Research Assistance (NRC-IRAP), to support a project focused...

Rapid Dose Therapeutics and McMaster University Awarded NSERC Research and Development Grant to Develop Oral Dissolvable Film for Enhanced Drug Delivery

January 23, 2020


Burlington, Ontario – January , 2020 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation“) is pleased to announce their newest research partnership program entitled “Rapid Delivery of Therapeutics via Dissolution of Polymeric Films” with McMaster University, located in Hamilton, Ontario, Canada. This...

Rapid Dose Therapeutics Announces Shareholder Meeting Voting Results and New Chief Financial Officer

December 6, 2019


Burlington, Ontario – December , 2019 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce that all of the nominees listed in the Corporation’s management information circular dated November 11, 2019 were elected as directors of the Corporation at...

Health Canada Grants Micro-Processing Licence to Rapid Dose

November 19, 2019


BURLINGTON, Ontario – November 19, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported that is has been issued a micro-processing licence by Health Canada for its Burlington, Ontario facility in accordance with the Cannabis Act and Cannabis Regulations. “This...

Rapid Dose Reports Second Quarter Financial Results, Provides Operations Update and Closes Private Placement

October 30, 2019


BURLINGTON, Ontario – October 30, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported its financial results for the second quarter of fiscal 2020, which ended on August 31, 2019. “We are very pleased to announce the recognition of revenue...

Rapid Dose Therapeutics Announces First Closing of Private Placement

October 9, 2019


BURLINGTON, Ontario, October 9, 2019 – Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) is pleased to announce that today it has completed the first closing of a private placement of common shares in the capital of the Corporation (“Common Shares”) at a...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16